WARSAW – 8 December 2025 – Greenberg Traurig advised FAGRON, a leading Dutch pharmaceutical group, on the acquisition of book of business from the Kraków-based Zakład Farmaceutyczny AMARA sp. z o.o., devoted to the production of pharmaceutical raw materials for prescription drugs.
This deal supports Fagron’s strategy to diversify its presence in dynamic markets and highlight its disciplined M&A approach as a driver of sustainable growth.
The Greenberg Traurig team, acting as the lead counsel in the transaction, was led by Local Partner Przemysław Furmaga, who was supported by Senior Associate Andrzej Dunikowski, Associate Patrycja Wakuluk and Junior Associate Bartłomiej Ciećwierz.
The interdisciplinary team also included: Senior Associate Jakub Baczuk, who provided advice on the IP aspects of the transaction. Partner Robert Gago supported by Associate Paweł Fortuna were responsible for the antitrust advice. Local Partner Maciej Kacymirow and Senior Associate Mateusz Rogulski advised on the tax aspects of the deal.
Local Partner Przemysław Furmaga provided overall supervision of the project.
Fagron N.V. is the leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies and clinics in more than 35 countries. The company develops and supplies a wide range of compounding products — including pharmaceutical raw materials, active ingredients and excipients — enabling healthcare professionals to prepare tailored medications.